益生菌对囊虫感染患者的抗炎作用

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine Pub Date : 2025-08-18 DOI:10.1016/j.cyto.2025.157013

Magda S.A. Abdeltawab , Shimaa M. Abdel Aal , Shaimaa Mohammed Ali , Kerolos Y.W. Zaki , Shimaa Saad El-Din , Noha M. Amin

{"title":"益生菌对囊虫感染患者的抗炎作用","authors":"Magda S.A. Abdeltawab , Shimaa M. Abdel Aal , Shaimaa Mohammed Ali , Kerolos Y.W. Zaki , Shimaa Saad El-Din , Noha M. Amin","doi":"10.1016/j.cyto.2025.157013","DOIUrl":null,"url":null,"abstract":"<div><div><em>Blastocystis hominis</em> BH infection has been linked to a variety of intestinal immunopathologies. Probiotic therapy is suggested to improve gastrointestinal inflammation during blastocystosis by inducing a pro-inflammatory cytokine response and modulating immune signaling pathways.</div><div>A hundred patients infected with BH were divided into 4 groups. Group 1: 20 patients did not receive any treatment; Group 2: 40 patients received probiotic therapy; Group 3: 20 patients received metronidazole; and Group 4: 20 patients received both metronidazole and probiotics. Metronidazole was administered at a dose of 250 mg three times daily for 10 days, whereas probiotic therapy consisted of Lacteol forte (<em>Lactobacillus acidophilus LB</em>) capsules twice daily for seven days. Patients were clinically evaluated for the outcome of gastrointestinal symptoms. In addition, fecal calprotectin (FCP) and tumor necrosis factor alpha (TNF-α) levels were measured by ELISA to assess intestinal inflammation and immune response.</div><div>Between-groups comparison for the presence of gastrointestinal symptoms after treatment did not show any significant difference except for the enhanced effect of probiotic therapy over metronidazole in relieving flatulence. Within-groups comparisons showed a significant reduction in the number of patients complaining of diarrhea in non-treated patients and in patients receiving combined treatment. A significant resolution of abdominal pain was observed among patients receiving probiotics. The number of patients suffering from flatulence significantly decreased in metronidazole and combined therapy-treated groups.</div><div>Assessment of FCP showed that the highest values were among non-treated patients, followed by patients receiving metronidazole, whereas the lowest values were detected in patients receiving probiotic therapy. As for the TNF-α levels, a significant reduction was observed in all patient groups.</div><div>Probiotic therapy alleviates intestinal inflammation in blastocystosis as indicated by the reduction of FCP and TNF-α after treatment and can also add a synergistic effect to that of metronidazole.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"195 ","pages":"Article 157013"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-inflammatory effect of probiotics in patients with Blastocystis spp. infection\",\"authors\":\"Magda S.A. Abdeltawab , Shimaa M. Abdel Aal , Shaimaa Mohammed Ali , Kerolos Y.W. Zaki , Shimaa Saad El-Din , Noha M. Amin\",\"doi\":\"10.1016/j.cyto.2025.157013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><em>Blastocystis hominis</em> BH infection has been linked to a variety of intestinal immunopathologies. Probiotic therapy is suggested to improve gastrointestinal inflammation during blastocystosis by inducing a pro-inflammatory cytokine response and modulating immune signaling pathways.</div><div>A hundred patients infected with BH were divided into 4 groups. Group 1: 20 patients did not receive any treatment; Group 2: 40 patients received probiotic therapy; Group 3: 20 patients received metronidazole; and Group 4: 20 patients received both metronidazole and probiotics. Metronidazole was administered at a dose of 250 mg three times daily for 10 days, whereas probiotic therapy consisted of Lacteol forte (<em>Lactobacillus acidophilus LB</em>) capsules twice daily for seven days. Patients were clinically evaluated for the outcome of gastrointestinal symptoms. In addition, fecal calprotectin (FCP) and tumor necrosis factor alpha (TNF-α) levels were measured by ELISA to assess intestinal inflammation and immune response.</div><div>Between-groups comparison for the presence of gastrointestinal symptoms after treatment did not show any significant difference except for the enhanced effect of probiotic therapy over metronidazole in relieving flatulence. Within-groups comparisons showed a significant reduction in the number of patients complaining of diarrhea in non-treated patients and in patients receiving combined treatment. A significant resolution of abdominal pain was observed among patients receiving probiotics. The number of patients suffering from flatulence significantly decreased in metronidazole and combined therapy-treated groups.</div><div>Assessment of FCP showed that the highest values were among non-treated patients, followed by patients receiving metronidazole, whereas the lowest values were detected in patients receiving probiotic therapy. As for the TNF-α levels, a significant reduction was observed in all patient groups.</div><div>Probiotic therapy alleviates intestinal inflammation in blastocystosis as indicated by the reduction of FCP and TNF-α after treatment and can also add a synergistic effect to that of metronidazole.</div></div>\",\"PeriodicalId\":297,\"journal\":{\"name\":\"Cytokine\",\"volume\":\"195 \",\"pages\":\"Article 157013\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytokine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043466625001607\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466625001607","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

人芽囊虫BH感染与多种肠道免疫病变有关。益生菌治疗被认为可以通过诱导促炎细胞因子反应和调节免疫信号通路来改善囊胚发育期间的胃肠道炎症。将100例BH感染者分为4组。第一组：20例患者未接受任何治疗；第二组：40例患者接受益生菌治疗；第三组：20例患者接受甲硝唑治疗；第4组：20例患者同时服用甲硝唑和益生菌。甲硝唑的剂量为250毫克，每天3次，持续10天，而益生菌治疗包括每日2次的乳酸菌胶囊，持续7天。临床评估患者胃肠道症状的结果。ELISA法检测大鼠粪便钙保护蛋白（FCP）和肿瘤坏死因子α (TNF-α)水平，评价肠道炎症和免疫反应。治疗后胃肠道症状的组间比较，除了益生菌治疗在缓解肠胃胀气方面的效果强于甲硝唑外，无显著差异。组内比较显示，在未接受治疗的患者和接受联合治疗的患者中，抱怨腹泻的患者人数显著减少。在服用益生菌的患者中观察到腹痛的显著缓解。甲硝唑组和联合治疗组胃胀气发生率显著降低。FCP评估显示，未接受治疗的患者FCP值最高，其次是接受甲硝唑治疗的患者，而接受益生菌治疗的患者FCP值最低。TNF-α水平在各患者组均显著降低。益生菌治疗可减轻囊胚发育的肠道炎症，治疗后可降低FCP和TNF-α，并可在甲硝唑的基础上增加协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Anti-inflammatory effect of probiotics in patients with Blastocystis spp. infection

查看原文本刊更多论文

Anti-inflammatory effect of probiotics in patients with Blastocystis spp. infection

Blastocystis hominis BH infection has been linked to a variety of intestinal immunopathologies. Probiotic therapy is suggested to improve gastrointestinal inflammation during blastocystosis by inducing a pro-inflammatory cytokine response and modulating immune signaling pathways.

A hundred patients infected with BH were divided into 4 groups. Group 1: 20 patients did not receive any treatment; Group 2: 40 patients received probiotic therapy; Group 3: 20 patients received metronidazole; and Group 4: 20 patients received both metronidazole and probiotics. Metronidazole was administered at a dose of 250 mg three times daily for 10 days, whereas probiotic therapy consisted of Lacteol forte (Lactobacillus acidophilus LB) capsules twice daily for seven days. Patients were clinically evaluated for the outcome of gastrointestinal symptoms. In addition, fecal calprotectin (FCP) and tumor necrosis factor alpha (TNF-α) levels were measured by ELISA to assess intestinal inflammation and immune response.

Between-groups comparison for the presence of gastrointestinal symptoms after treatment did not show any significant difference except for the enhanced effect of probiotic therapy over metronidazole in relieving flatulence. Within-groups comparisons showed a significant reduction in the number of patients complaining of diarrhea in non-treated patients and in patients receiving combined treatment. A significant resolution of abdominal pain was observed among patients receiving probiotics. The number of patients suffering from flatulence significantly decreased in metronidazole and combined therapy-treated groups.

Assessment of FCP showed that the highest values were among non-treated patients, followed by patients receiving metronidazole, whereas the lowest values were detected in patients receiving probiotic therapy. As for the TNF-α levels, a significant reduction was observed in all patient groups.

Probiotic therapy alleviates intestinal inflammation in blastocystosis as indicated by the reduction of FCP and TNF-α after treatment and can also add a synergistic effect to that of metronidazole.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.